Jacobs Levy Equity Management
RARX

Jacobs Levy Equity Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Jacobs Levy Equity Management’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,736
Closed -$195K – 1086
2018
Q4 		$195K Buy
+10,736
New +$169K ﹤0.01% 888
2018
Q1 		– Sell
-46,660
Closed -$397K – 1103
2017
Q4 		$397K Buy
+46,660
New +$574K 0.01% 798

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MMPI
Morgenthaler Management Partners IX Portola Valley, California $22.6M AUM
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management's RARX Position: Q1 2019 in Review

Jacobs Levy Equity Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q1 2019, closing a stake of 10,736 shares — an estimated $195K sold.

Jacobs Levy Equity Management first reported a position in RARX in Q4 2017 and held it in 2 quarters. The position peaked at $397K in Q4 2017. 124 funds tracked by Wall St. Rank hold RARX as of Q1 2019.

  • Jacobs Levy Equity Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 10,736 Ra Pharmaceuticals, Inc. Common Stock shares in Q1 2019, an estimated $195K.
  • Jacobs Levy Equity Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $397K in Q4 2017.
  • 124 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q1 2019.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2019, filed 14 May 2019.